[Home](https://github.com/mm80843/T3.5/blob/main/docs/index.md) >> Class: [Benef](https://github.com/mm80843/T3.5/tree/main/docs/Benef/index.md) >> Individual ID:PBN__Benef_663 

# __Accelerated drug testing__

## Description of Benefits pertaining to Beneficiaries

* [Private investors in pharmaceutical companies would benefit from accelerated drug development, leading to potentially faster market entry and revenue generation.](https://github.com/mm80843/T3.5/blob/main/docs/BenefReturn/PBN__BenefReturn_709.md)

## Stakeholders benefitting from this Benefit

* [researchers](https://github.com/mm80843/T3.5/blob/main/docs/Stakeholder/PBN__Stakeholder_2.md)
* [pharmaceutical companies](https://github.com/mm80843/T3.5/blob/main/docs/Stakeholder/PBN__Stakeholder_124.md)

## Articles mentionning this Benefit

* [Exploring the Potential of Artificial Intelligence and Machine Learning to Combat COVID-19 and Existing Opportunities for LMIC: A Scoping Review](https://github.com/mm80843/T3.5/blob/main/docs/Article/PBN__Article_131.md)

## Name of the Benefit

AI technology can speed up drug testing and discovery, allowing for faster development of treatments for COVID-19 and other diseases.

